Search the Newsreel

Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards

Mineralys Therapeutics (Nasdaq: MLYS) announced that its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson on August 10, 2026. These awards include a stock option for 135,000 shares and a restricted stock unit (RSU) award for 102,400 …

Verisk Analytics (VRSK) Eps Diluted (Quarterly)

HCAT Maintains by Wells Fargo -- Price Target Lowered to $1.50

Wells Fargo has maintained an Equal-Weight rating for Health Catalyst (HCAT) but lowered its price target to $1.50 from $1.75, citing concerns over growth expectations in a challenging healthcare environment. Despite this, GuruFocus assesses HCAT as 57.3% undervalued with a GF Value™ of $4.16 …

Is VRSK Worth Buying as Recurring Revenue Battles a Premium Valuation?

Verisk Analytics (VRSK) presents a durable subscription model with strong cash generation, but its premium valuation raises questions about its justification. While subscription revenues and product investments offer predictability, the company faces increased financing costs and operating expenses, requiring strong execution to maintain its …

Verisk's AI Expansion Gains Traction as Insurance Adoption Scales

Verisk (VRSK) is significantly expanding its AI integration within the insurance sector, with increased adoption of its XactAI platform and the rollout of Core Lines Reimagine modules. The company is seeing positive indicators in subscription revenue growth and upward revisions in earnings estimates, suggesting …

What is HC Wainwright's Estimate for MLYS FY2030 Earnings?

This REIT Boasts A Sizzling 12.9% Yield. Should It Be On Your Radar?

Annaly Capital Management offers a sizzling 12.9% yield. But the REIT's strategy is not risk-free. Continue Reading

Kalyani Investment Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Qualys (NASDAQ:QLYS) Upgraded at Zacks Research

Zacks Research has upgraded Qualys (NASDAQ:QLYS) from a "hold" to a "strong-buy" rating. This upgrade comes after Qualys reported strong quarterly earnings, beating analyst estimates for EPS and showing significant revenue growth. Despite the upgrade, the broader analyst consensus remains "hold" with an average …

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J To Go Ex-Dividend On September 1st, 2026 With 0.55469 USD Dividend Per Share

ANNALY CAPITAL MANAGEMENT INC will go ex-dividend on September 1st, 2026, for its 8.875 CUM PREF SER J shares. Shareholders will receive a dividend of 0.55469 USD per share.

Kalyani Investment Q1 Results: Consolidated PAT turns positive, OCI surges

Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised 2,170 stock options for common stock at $16.00 per share and subsequently sold those 2,170 shares at $27.09 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted …

Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings

Avalyn Pharma (NASDAQ:AVLN) shares reached a new 52-week high of $39.99 after reporting a quarterly loss of $0.98 per share, which surpassed analysts' expectations of a $1.03 loss. Analyst sentiment remains largely positive, with a consensus "Buy" rating and an average price target of …

Verisk (VRSK) Tried to Walk Away From a $2.35 Billion Deal. A Judge Sent It Back

Verisk Analytics, Inc. (NASDAQ:VRSK) believed it had made a clean break from its $2.35 billion cash deal. A Delaware judge just told the data-analytics company otherwise, ordering it to return to the altar. The issue dates back to July 2025, when Verisk agreed to …

5 Revealing Analyst Questions From Qualys’s Q2 Earnings Call

5 Revealing Analyst Questions From Qualys's Q2 Earnings Call Qualys posted a strong second quarter, with results surpassing market expectations and prompting a notably positive market reaction. Management attributed the quarter's performance to heightened demand for its AI-native risk operations platform and new capabilities …

Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock

Mineralys Therapeutics insider David Malcom Rodman sold 2,170 shares of the company's stock for $58,785.30, reducing his holdings by 4.05%. This transaction, conducted under a pre-arranged Rule 10b5-1 plan, follows several other sales by Rodman in recent months. The company recently reported a significant …

Mineralys Therapeutics CMO David Rodman sells $58,785 in stock

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,170 shares for $58,785 and exercised stock options for an equal number of shares. These transactions were part of a Rule 10b5-1 trading plan. The company's shares show a significant annual return despite a year-to-date …

Investors Can Find Comfort In Verisk Analytics' (NASDAQ:VRSK) Earnings Quality

Despite reported weak earnings, an analysis of Verisk Analytics (NASDAQ:VRSK) suggests optimism due to the overall quality of its income statement, particularly its strong free cash flow relative to profit. The company's accrual ratio of -0.13 indicates that its statutory earnings were less than …

5 Must-Read Analyst Questions From Health Catalyst’s Q2 Earnings Call

Health Catalyst (HCAT) reported a notable decline in Q2 sales, attributed to client migrations and divestiture of its Vitalware business. While revenue slightly beat analyst estimates, the company lowered its full-year guidance and faces ongoing structural challenges in health systems. Analysts pressed management on …

Annaly Capital Management, Inc. Announces Preferred Dividends

Annaly Capital Management, Inc. has announced cash dividends for its Series F, G, I, and J Preferred Stocks for the third quarter of 2026. The dividends, with varying rates based on CME Term SOFR plus a spread, are payable on September 30, 2026, to …

Qualys (QLYS) Upgraded to Strong Buy: Here's Why

Qualys (QLYS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's …

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down After Earnings Miss

Here's Why You Should Retain VRSK Stock in Your Portfolio Now

Shares of Verisk Analytics, Inc. VRSK have had a decent run over the past three months. The stock has risen 12.1%, outperforming the industry's 9.1% growth. The Zacks S&P 500 composite has risen 3% over the said time frame. VRSK has a Growth Score …

Why Karnalyte Resources Inc. stock fell yesterday

Avalyn: Q2 Earnings Snapshot

Avalyn Pharma Inc. Q2 2026: Net loss $(28.9M), EPS $(0.98) — 10-Q Summary

Avalyn Pharma Inc. reported a wider net loss of $(28.9M) in Q2 2026, compared to $(20.2M) in Q2 2025, with basic and diluted net loss per share at $(0.98). The clinical-stage biotech company continues to invest in its development programs, including AP01, AP02, and …

Avalyn Pharma reports Q2 2026 net loss $28.9M; cash $413.5M, runway into 2029

Avalyn Pharma reported a Q2 2026 net loss of $28.9 million, ending the period with $413.5 million in cash, which is projected to fund operations into 2029. The company saw increased R&D and G&A expenses due to clinical activity and headcount. Key business highlights …

Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com

This article reports that Avalyn Pharma Inc. has filed a Form 8K for August 12, as reported by Investing.com. The filing is brief and does not provide further details within the article content. It is categorized under stock market news.

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma Inc. announced its financial results for the second quarter ended June 30, 2026, and highlighted recent business achievements, including the completion of enrollment for its MIST global Phase 2b trial of AP01 with 398 patients. The company reported $413.5 million in cash, …

Singapore's Audience Analytics H1 profit jumps on higher contracted services fulfilment

Audience Analytics Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics reported a wider second-quarter loss due to a $200 million payment for an amended agreement with Tanabe Pharma, but is progressing with commercial-launch preparations for lorundrostat ahead of its December PDUFA date. The company highlighted positive clinical data for lorundrostat in various …

Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts

Five research firms have issued a consensus "Buy" rating for Avalyn Pharma Inc. (NASDAQ:AVLN), with an average 12-month price target of $59.00. The company recently reported a quarterly loss of $21.83 per share, missing analyst estimates, and currently has a market capitalization of $1.57 …

Health Catalyst sells VitalWare for $147Mn

Health Catalyst sold its VitalWare subsidiary to Med-Metrix for $147 million in cash, completed on July 31, 2026. This divestiture allowed Health Catalyst to eliminate its credit facility and focus entirely on healthcare intelligence, analytics, and AI. VitalWare, which provides mid-revenue cycle management solutions, …

Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.5, Implies 77% Upside

The average 12-month price target for Mineralys Therapeutics, Inc. (MLYS) stock has been slightly reduced from $49 to $48.5 by 8 analysts, with forecasts ranging from $30 to $56 per share. This new target suggests a potential upside of approximately 77% from the August …

How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback

Mineralys Therapeutics reported a wider Q2 2026 net loss of US$241.07 million, alongside confirming a December 22, 2026 PDUFA target date for its lead asset, lorundrostat, and repurchasing a royalty obligation. This update highlights management's dual focus on regulatory progress and enhancing long-term economics, …